Skip to Content
Merck
All Photos(1)

Key Documents

View All Documentation

71650

Sigma-Aldrich

Sodium phosphate dibasic dodecahydrate

puriss. p.a., crystallized, ≥99.0% (T)

Synonym(s):

sec-Sodium phosphate, Disodium hydrogen phosphate dodecahydrate, Disodium phosphate, di-Sodium hydrogen phosphate dodecahydrate

Sign Into View Organizational & Contract Pricing
All Photos(1)

About This Item

Linear Formula:
Na2HPO4 · 12H2O
CAS Number:
10039-32-4
Molecular Weight:
358.14
EC Number:
231-448-7
MDL number:
MFCD00149181
UNSPSC Code:
12161700
PubChem Substance ID:
329763400
NACRES:
NA.21
Assay:
≥99.0% (T)
form:
crystals
solubility:
water: soluble 35.8 g/L at 20 °C
Pricing and availability is not currently available.

grade

puriss. p.a.

Quality Level

200

Assay

≥99.0% (T)

form

crystals

quality

crystallized

pH

9.0-9.3 (25 °C, 50 mg/mL in H2O)

solubility

water: soluble 35.8 g/L at 20 °C

anion traces

chloride (Cl-): ≤5 mg/kg
fluoride (F-): ≤5 mg/kg
sulfate (SO42-): ≤50 mg/kg

cation traces

As: ≤0.5 mg/kg
Ca: ≤10 mg/kg
Cd: ≤5 mg/kg
Co: ≤5 mg/kg
Cr: ≤5 mg/kg
Cu: ≤5 mg/kg
Fe: ≤5 mg/kg
K: ≤50 mg/kg
Mg: ≤5 mg/kg
Mn: ≤5 mg/kg
Ni: ≤5 mg/kg
Pb: ≤5 mg/kg
Zn: ≤5 mg/kg

SMILES string

O.O.O.O.O.O.O.O.O.O.O.O.[Na+].[Na+].OP([O-])([O-])=O

InChI

1S/2Na.H3O4P.12H2O/c;;1-5(2,3)4;;;;;;;;;;;;/h;;(H3,1,2,3,4);12*1H2/q2*+1;;;;;;;;;;;;;/p-2

InChI key

DGLRDKLJZLEJCY-UHFFFAOYSA-L

Looking for similar products? Visit Product Comparison Guide

General description

Sodium phosphate is a colorless crystalline sodium salt. It is widely used as a buffer in molecular biology, biochemistry, and chromatographic studies. It exists in three forms: monobasic (NaH2PO4), dibasic (Na2HPO4), and tribasic (Na3PO4). Monobasic and dibasic forms in varying ratios are commonly used to compose the neutral sodium phosphate buffer solution.

Application

Sodium phosphate dibasic dodecahydrate may be used to prepare the 0.1M phosphate buffer having pH 7.4.[1]

Storage Class Code

13 - Non Combustible Solids

WGK

WGK 1

Flash Point(F)

Not applicable

Flash Point(C)

Not applicable

Choose from one of the most recent versions:

Certificates of Analysis (COA)

Lot/Batch Number
BCCM6212
BCCK7964
BCCH7399
BCCJ5385
BCCG6363

Don't see the Right Version?

If you require a particular version, you can look up a specific certificate by the Lot or Batch number.

Search for a COA

Already Own This Product?

Find documentation for the products that you have recently purchased in the Document Library.

Visit the Document Library

Chia Lin Chang et al.
Evidence-based complementary and alternative medicine : eCAM, 2012, 125247-125247 (2011-07-15)
The objectives of this study were to determine phytochemical compositions, chemiluminescence antioxidant activities, and neuroprotective effects on PC12 cells for water, methanol, and 95% ethanol extracts of the air-dried fruit of Terminalia chebula Retzius. The water extract afforded the greatest
Karen Sliwa et al.
Heart (British Cardiac Society), 100(24), 1967-1974 (2014-09-18)
Lack of evidence-based data on the spectrum of cardiovascular disease (CVD) in pregnancy or in the postpartum period, as well as on maternal and fetal outcome, provides challenges for treating physicians, particularly in areas of low resources. The objectives of
Yuichiro Yano et al.
Journal of the American College of Cardiology, 65(4), 327-335 (2015-01-31)
Isolated systolic hypertension (ISH), defined as systolic blood pressure (SBP) ≥140 mm Hg and diastolic blood pressure (DBP) <90 mm Hg, in younger and middle-aged adults is increasing in prevalence. The aim of this study was to assess the risk
Luciano Candilio et al.
Heart (British Cardiac Society), 101(3), 185-192 (2014-09-26)
Remote ischaemic preconditioning (RIPC), using brief cycles of limb ischaemia/reperfusion, is a non-invasive, low-cost intervention that may reduce perioperative myocardial injury (PMI) in patients undergoing cardiac surgery. We investigated whether RIPC can also improve short-term clinical outcomes. One hundred and
Matthew R Weir et al.
Journal of clinical hypertension (Greenwich, Conn.), 16(12), 875-882 (2014-10-21)
The effects of canagliflozin, a sodium glucose co-transporter 2 inhibitor, on blood pressure (BP) and osmotic diuresis- and intravascular volume reduction-related adverse events (AEs) were evaluated using pooled data from four placebo-controlled, phase 3 studies in patients with type 2
View All Related Papers

Questions

Reviews

No rating value

Active Filters

Our team of scientists has experience in all areas of research including Life Science, Material Science, Chemical Synthesis, Chromatography, Analytical and many others.

Contact Technical Service